Leerink Partners: Upgraded the Tandem Diabetes Care (TNDM.US) rating from the market unanimously to superior to the market rating, and the target price was adjusted from $34.00 to $45.00.

Leerink Partners: Upgraded the Tandem Diabetes Care (TNDM.US) rating from the market unanimously to superior to the market rating, and the target price was adjusted from $34.00 to $45.00.

Zhitong FinanceApr 25 21:11

Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target Is $45

Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45.

MT NewswiresApr 25 19:12

Cracking The Code: Understanding Analyst Reviews For Tandem Diabetes Care

Ratings for Tandem Diabetes Care (NASDAQ:TNDM) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent

BenzingaApr 24 03:01

Tandem Diabetes Care Is Maintained at Buy by Stifel

Tandem Diabetes Care Is Maintained at Buy by Stifel

Dow JonesApr 24 01:12

Stifel Maintains Buy on Tandem Diabetes Care, Raises Price Target to $40

Stifel analyst Mathew Blackman maintains Tandem Diabetes Care with a Buy and raises the price target from $37 to $40.

Analyst UpgradesApr 24 01:01

Insider Stock Buying Reaches US$725.5k On Tandem Diabetes Care

Usually, when one insider buys stock, it might not be a monumental event.

Simply Wall StApr 16 19:12